



US006432918B1

(12) **United States Patent**
Winslow

(10) **Patent No.:** US 6,432,918 B1
(45) **Date of Patent:** *Aug. 13, 2002

(54) **METHODS AND COMPOSITIONS FOR OPTIMIZATION OF OXYGEN TRANSPORT BY CELL-FREE SYSTEMS**

(75) Inventor: **Robert M. Winslow**, La Jolla, CA (US)

(73) Assignee: **The Regents of the University of California**, Oakland, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/544,656**

(22) Filed: **Apr. 5, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/032,342, filed on Feb. 27, 1998, now Pat. No. 6,054,427, which is a continuation-in-part of application No. 08/810,694, filed on Feb. 28, 1997, now Pat. No. 5,814,601.

(51) **Int. Cl.** ⁷ A61K 38/16; A61K 35/14

(52) **U.S. Cl.** 514/6; 514/21; 514/832; 514/833; 530/385; 530/402; 530/813; 530/815; 530/829; 429/529

(58) **Field of Search** 514/6, 21, 832, 514/833; 530/385, 402, 813, 815, 829; 424/529

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,925,344 A	12/1975	Mazur	260/112.5
3,956,259 A	5/1976	Garcia et al.	260/112 B
4,001,200 A	1/1977	Bonsen et al.	260/112.5 R
4,001,401 A	* 1/1977	Bonsen et al.	424/177
4,053,590 A	10/1977	Bonsen et al.	424/177
4,061,736 A	* 12/1977	Morris et al.	424/177
4,064,118 A	* 12/1977	Wong	514/6
4,113,853 A	* 9/1978	Funakoshi et al.	514/6
4,133,874 A	1/1979	Miller et al.	424/38
4,179,337 A	12/1979	Davis et al.	435/181
4,301,144 A	11/1981	Iwashita et al.	424/78
4,316,093 A	2/1982	Broers et al.	250/492.1
4,336,248 A	6/1982	Bonhard et al.	424/101
4,377,512 A	3/1983	Ajisaka et al.	260/112 B
4,401,652 A	8/1983	Simmonds et al.	424/101
4,412,989 A	11/1983	Iwashita et al.	424/177
4,439,357 A	3/1984	Bonhard et al.	260/112 B
4,473,494 A	9/1984	Tye	260/112 B
4,473,496 A	9/1984	Scannon	260/112 B
4,526,715 A	7/1985	Kothe et al.	260/112 B
4,529,719 A	7/1985	Tye	514/6
4,532,130 A	7/1985	Djordjevich et al.	424/101
4,584,130 A	4/1986	Bucci et al.	260/115
4,598,064 A	7/1986	Walder	514/6
4,600,531 A	7/1986	Walder	530/385
4,650,786 A	* 3/1987	Wong	514/6
4,670,417 A	* 6/1987	Iwasaki et al.	514/6
4,710,488 A	12/1987	Wong	514/6
4,730,936 A	3/1988	Thorjusen, Jr.	366/101
4,738,952 A	* 4/1988	Ecanow et al.	514/6

4,777,244 A	10/1988	Bonhard et al.	530/385
4,826,811 A	5/1989	Sehgal et al.	514/6
4,831,012 A	5/1989	Estep	514/6
4,857,636 A	8/1989	Hsia	530/385
4,861,867 A	8/1989	Estep	530/385
4,900,780 A	* 2/1990	Cermey	525/54.1
4,911,929 A	3/1990	Farmer et al.	424/450
4,920,194 A	* 4/1990	Filler et al.	530/385
4,987,154 A	1/1991	Long, Jr.	514/772

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

EP	0 361 719 A1	4/1990
WO	87/07832	12/1987
WO	90/13309	11/1990
WO	91/07190	5/1991

OTHER PUBLICATIONS

Mirhashemi et al., "Model analysis of the enhancement of tissue oxygenation by hemodilution due to increased microvascular flow velocity," *Microvasc. Res.* 34:290–301 (1987).

Mirhashemi et al., "Effects of hemodilution on skin microcirculation," *Am. J. Physiol.* 254:H411–H416 (1988).

Tsai and Intaglietta, "Local tissue oxygenation by statistically distributed sources," *Microvasc. Res.* 44:200–213 (1992).

Tsai et al., "Microcirculatory consequences of blood substitution with $\alpha\alpha$ -hemoglobin," in Winslow et al., (eds.), *Blood Substitutes. Physiological Basis of Efficacy*, Birkhäuser, Boston, MA, pp. 155–174 (1995).

Stettler et al., "Influence of a Recombinant Hemoglobin Solution on Blood Rheology," *Transfusion* 37:1149–1155 (1997).

Iwasaki and Iwashita, "Preparation and Evaluation of Hemoglobin-Polyethylene Glycol Conjugate (Pyridoxalated Polyethylene Glycol Hemoglobin) as an Oxygen-Carrying Resuscitation Fluid," *Artif. Organs* 10:411–416 (1986).

Intaglietta, "Whitaker Lecture 1996: Microcirculation, Biomedical Engineering, and Artificial Blood," *Ann. Biomed. Engineer.* 25:593–603 (1997).

Simoni et al., "An Improved Blood Substitute," In Vivo Evaluation of its Hemodynamic Effects, *ASAIO J.*, 42:M773–782 (1996).

Guyton, *Human Physiology And Mechanisms Of Disease* (3rd. ed.; W.B. Saunders Co., Philadelphia, PA), pp. 228–229 (1982).

Primary Examiner—Christopher S. F. Low

Assistant Examiner—Abdel A. Mohamed

(74) **Attorney, Agent, or Firm**—Medlen & Carroll, LLP

(57)

ABSTRACT

Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander may consist of any suitable diluent.